Adipocytic sclerostin loop3-LRP4 interaction required by sclerostin to impair whole-body lipid and glucose metabolism.

Summary

Serum sclerostin was elevated in POP with T2DM and in newly diagnosed T2DM. Blocking adipocyte-specific sclerostin loop3-LRP4 interactions ameliorated sclerostin-induced dyslipidemia and dysglycemia in vitro and in vivo, suggesting a therapeutically distinct and potentially cardiovascularly safer approach than loop2-directed antibodies.

Key Findings

• Serum sclerostin levels are elevated in POP with T2DM and in newly diagnosed T2DM.
• Sclerostin loop3 contributes to whole-body lipid and glucose metabolic impairment in vivo.
• Blocking adipocytic sclerostin loop3–LRP4 interaction reverses sclerostin-induced metabolic defects in vitro and in vivo.

Clinical Implications

Supports development of loop3-LRP4–selective sclerostin inhibitors to improve glucose and lipid metabolism in patients with POP and T2DM while potentially mitigating cardiovascular risk seen with current agents.

Limitations

• Preclinical nature without randomized clinical trials; human efficacy and safety remain to be established.
• Potential off-target effects and long-term metabolic/osteoskeletal consequences of loop3-specific inhibition are unknown.

Future Directions

Develop selective loop3-LRP4 antagonists, assess metabolic efficacy and cardiovascular safety in large animal models, and progress to early-phase human trials in POP with T2DM.